PetMed Express (PETS) Expected to Release Earnings on Thursday

PetMed Express (NASDAQ:PETS) is projected to release its Q1 2027 results after the market closes on Thursday, August 13th. Analysts expect PetMed Express to announce earnings of $0.12 per share and revenue of $71.00 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2027 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

PetMed Express (NASDAQ:PETS) last posted its quarterly earnings results on Tuesday, June 2nd. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The firm had revenue of $42.82 million for the quarter, compared to analysts’ expectations of $52.00 million. PetMed Express had a negative net margin of 32.00% and a negative return on equity of 76.86%. During the same quarter in the previous year, the company earned ($0.56) EPS. On average, analysts expect PetMed Express to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

PetMed Express Stock Down 0.5%

Shares of PETS opened at $1.97 on Tuesday. PetMed Express has a twelve month low of $1.57 and a twelve month high of $4.10. The company has a market capitalization of $42.10 million, a P/E ratio of -0.72 and a beta of 0.76. The firm has a 50 day moving average of $1.90 and a 200 day moving average of $2.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PETS. Steel Partners Holdings L.P. purchased a new position in PetMed Express during the fourth quarter valued at approximately $620,000. Federated Hermes Inc. increased its stake in shares of PetMed Express by 30.1% in the fourth quarter. Federated Hermes Inc. now owns 627,743 shares of the company’s stock worth $2,009,000 after purchasing an additional 145,357 shares in the last quarter. Bridgeway Capital Management LLC increased its stake in shares of PetMed Express by 164.3% in the third quarter. Bridgeway Capital Management LLC now owns 107,816 shares of the company’s stock worth $271,000 after purchasing an additional 67,016 shares in the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of PetMed Express during the 3rd quarter valued at $153,000. Finally, UMB Bank n.a. bought a new stake in shares of PetMed Express during the 4th quarter valued at $192,000. Hedge funds and other institutional investors own 73.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on PETS shares. Weiss Ratings raised PetMed Express from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Zacks Research raised PetMed Express to a “hold” rating in a research report on Thursday, April 30th. Finally, Wall Street Zen upgraded PetMed Express from a “strong sell” rating to a “hold” rating in a report on Saturday, June 6th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

About PetMed Express

PetMed Express, Inc operates as an online and catalog-based pet pharmacy and retail supplier under the 1-800-PetMeds brand name. The company distributes prescription and non‐prescription medications, nutritional supplements, flea and tick control products, and a range of pet health supplies directly to consumers. Through its licensed veterinary pharmacy in Delray Beach, Florida, PetMed Express fills orders for dogs, cats and other companion animals, offering both branded and generic products alongside its own private‐label formulations.

Founded in 1996 by Marc Puleo, PetMed Express built its business on the premise of convenience and cost savings for pet owners seeking reliable access to veterinary medications.